New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo

Leukemia and Lymphoma

Volumn 48, Issue 6, 2007, Pages 1179-1186

  Braschoss, Sandra ^a   Hirsch, Burkhard ^a   Dübel, Stefan ^b   Stein, Harald ^a   Dürkop, Horst ^a  

^a Institut fur Pathologie   (Germany)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

ALCL; CD30; Hodgkin lymphoma; Immunotherapy; Lymphoma; Ribonuclease; Therapy

Indexed keywords

ANTIBODY; CD30 ANTIGEN; IMMUNOTOXIN; PANCREATIC RIBONUCLEASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSFECTION; HODGKIN DISEASE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, CD30; CELL LINE; CELL PROLIFERATION; CYTOTOXINS; DROSOPHILA MELANOGASTER; FEMALE; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; RIBONUCLEASE, PANCREATIC; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED;

EID: 34347348143     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701272264     Document Type: Article

References (25)

1. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D. and German Hodgkin's Lymphoma Study Group (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med, 348, pp. 2386-2395.
2. Cutuli, B., Borel, C., Dhermain, F., Magrini, S. M., Wasserman, T. H. and Bogart, J. A. (2001) Breast cancer occurred after treatment for Hodgkin's disease: Analysis of 133 cases. Radiother Oncol, 59, pp. 247-255.
3. Stein, H., Foss, H. D., Dürkop, H., Marafioti, T., Delsol, G. and Pulford, K. (2000) CD30 anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood, 96, pp. 3681-3695.
4. Dürkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B. and Stein, H. (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family which is characteristic for Hodgkin's disease. Cell, 68, pp. 421-427.
5. Schwarting, R., Gerdes, J., Dürkop, H., Falini, B., Pileri, S. and Stein, H. (1989) Ber-H2: A new anti Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood, 74, pp. 1678-1689.
6. Schnell, R., Borchmann, P., Schulz, H. and Engert, A. (2002) Current strategies of antibody-based treatment in Hodgkin's disease. Ann Oncol, 13, pp. 57-66.
7. Baluna, R., Ghetie, V., Oppenheimer-Marks, N. and Vitetta, E. S. (1996) Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells. Int J Immunopharmacol, 18, pp. 355-361.
8. Youle, R. J. and D'Alessio, G. (1997) Antitumor RNases. Ribonucleases: Structures and Functions, pp. 491-511. Academic Press, New York
9. Saxena, S. K., Rybak, S. M., Winkler, G., Meade, H. M., McGray, P. and Youle, R. J. (1991) Comparison of RNases and toxins upon injection into Xenopus oocytes. J Biol Chem, 266, pp. 21208-21214.
10. Psarras, K., Ueda, M., Tanabe, M., Kitajima, M., Aiso, S. and Komatsu, S. (2000) Targeting activated lymphocytes with an entirely human immunotoxin analogue: Human pancreatic RNase1-human-IL-2 fusion. Cytokine, 12, pp. 786-790.
11. Huhn, M., Sasse, S., Tur, M. K., Matthey, B., Schinköthe, T. and Rybak, S. M. (2001) Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res, 61, pp. 8737-8742.
12. Stöcker, M., Tur, M. K., Sasse, S., Krüßmann, A., Barth, S. and Engert, A. (2003) Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif, 28, pp. 211-219.
13. Zewe, M., Rybak, S. M., Dübel, S., Coy, J. F., Welschof, M. and Newton, D. L. (1997) Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology, 3, pp. 127-136.
14. Drexler, H. G. (2001) The Leukemia-Lymphoma Cell Line Facts Book, Academic Press, San Diego
15. Nanni, P., de Giovanni, C., Lollini, P. L., Nicoletti, G. and Prodi, G. (1983) TS/A: A new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis, 1, pp. 373-380.
16. Schneider, I. (1972) Cell lines derived from late embryonic stages of Drosophila melanogaster. J Embryol Exp Morphol, 27, pp. 363-365.
17. Huston, J. S., Levinson, D., Medgett-Hunter, M., Tai, M. S., Novotny, J. and Margolies, M. N. (1988) Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA, 85, pp. 5879-5883.
18. Dübel, S., Breitling, F., Klewinghaus, I. and Little, M. (1992) Regulated secretion and purification of recombinant antibodies in E. coli. Cell Biophys, 21, pp. 69-79.
19. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M. and Stroiber, W. (2006) Current Protocols in Immunolgy, John Wiley, New York
20. Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S. and Giardina, S. (2000) Phase I trial of recombinant immunotoxin antiTac(Fv)-PE3 (LMB-2) in patients with hematologic malignancies. J Clin Oncol, 18, pp. 1622-1636.
21. Hofsteenge, J. (1997) Ribonuclease inhibitor. Ribonucleases: Structures and Functions, pp. 621-658. Academic Press, New York
22. Murthy, B. S. and Sirdeshmukh, R. (1992) Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor. Biochem J, 281, pp. 343-348.
23. Gaur, D., Swaminathan, S. and Batra, J. K. (2001) Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor. J Biol Chem, 276, pp. 24978-24984.
24. Matousek, J. (2001) Ribonucleases and their antitumor activity. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 129, pp. 175-191.
25. Futami, J., Maeda, T., Kitazoe, M., Nukui, E., Tada, H. and Seno, M. (2001) Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry, 40, pp. 7518-7524.